Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Merkel Cell 21Melanoma 9Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Sezary Syndrome 1Sarcoma 1Primary Myelofibrosis 1Mycosis Fungoides 1Motor Activity 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 2Nivolumab 2Ipilimumab 2Exercise 2cemiplimab 1avelumab 1Psychology, Positive 1Methods 1Immunotherapy 1Immune Checkpoint Inhibitors 1Diet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Motor Activity × avelumab × Dermatologic × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡